Mark Zdeblick

Portola Valley, CA, United States of America

Mark Zdeblick

This inventor holds 109 USPTO granted patents and 46 published patent applications, plus 15 CIPO patents and 12 EPO patents, primarily in Ingestible Technology (CPC class A61B5-073). Top assignees: Proteus Digital Health, Inc., Otsuka Pharmaceutical Company, Limited, Redwood Microsystems, Inc.. Active years: 2000-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark Zdeblick. Retrieved from https://idiyas.com/inventor/mark-zdeblick

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 109 

% Patents Active = 85.3

 

 

Average Co-Inventor Count = 2.4

ph-index = 38

Forward Citations = 4,949(Granted Patents)

Forward Citations (Not Self Cited) = 4,182(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Portola Valley, CA (US) (2000 - 2024)
  • Portolla Valley, CA (US) (2024)

Company Filing History:


Years Active: 2000-2024

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Ingestible Devices
Pharma-Informatics
Communication Systems
Supply Chain Management
Electromagnetic Sensing
Patient Customization
Data Gathering
Biofeedback
Mobile Device Integration
Event Marker Systems
Controlled Activation
Signal Decoding
109 patents (USPTO):Explore Patents

Title: Mark Zdeblick: A Pioneer in Pharma-informatics Systems and Controlled Activation Ingestible Identifiers

Introduction:

Mark Zdeblick, a talented inventor hailing from Portola Valley, CA, has made significant contributions to the field of innovation through his impressive patent portfolio. With over 106 patents to his name, Zdeblick has cemented his position as a leading figure in the realm of pharmaceutics and electronic devices. This article explores some of his latest patents, career highlights, collaborations, and the invaluable impact he has made in the industry.

Latest Patents:

Zdeblick's latest patents demonstrate his expertise in developing cutting-edge technologies. One of his groundbreaking inventions includes the Pharma-informatics system – an apparatus designed to provide power and transmit encoded information within a conducting medium. By utilizing different materials and conductance variables, this system holds immense potential in revolutionizing the field of healthcare and data transmission.

Another significant patent by Zdeblick is the Controlled Activation Ingestible Identifier. This innovation involves the integration of electrodes or materials within a pharmaceutically acceptable carrier, along with a circuit capable of generating signals when powered by a partial power source. The dissolvable barrier further enhances its applicability, allowing for the seamless integration of this identifier within the human body.

Career Highlights:

Mark Zdeblick's career has been punctuated by exceptional achievements and breakthrough inventions. He has been associated with renowned companies in the industry, including Proteus Digital Health, Inc. and Proteus Biomedical, Inc. These companies have played a pivotal role in advancing healthcare technologies, and Zdeblick's contributions have strengthened their positions as leaders in this space.

Collaborations:

Zdeblick's innovative mindset and collaborative spirit have led him to work with notable individuals in the field. Among his accomplished colleagues are Timothy Robertson and Hooman Hafezi, who have undoubtedly contributed to the success of various projects and played an integral role in the revolutionary advancements made by Zdeblick.

Conclusion:

Mark Zdeblick's prowess as an inventor and his numerous patents highlight his remarkable contributions to the field of innovations and patents. His impactful work in pharmaceutics and electronic devices has undoubtedly revolutionized the healthcare industry. With his ongoing dedication to pushing the boundaries of what is possible, Zdeblick continues to shape the future of science and technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…